Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3271-3279

  Vesga, Omar ^a   Agudelo, Maria ^a   Salazar, Beatriz E ^a   Rodriguez, Carlos A ^a   Zuluaga, Andres F ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; VANCOMYCIN;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOEQUIVALENCE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TREATMENT FAILURE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUGS, GENERIC; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THERAPEUTIC EQUIVALENCY; THIGH; TREATMENT FAILURE; VANCOMYCIN;

EID: 77955389721     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01044-09     Document Type: Article

References (43)

1. Adelman, C. C., and J. Norris. 2001. Usefulness of foreign aid for health care in less-developed countries. Lancet 358:2174.
2. Bauer, J., S. Spanton, R. Henry, J. Quick, W. Dziki, W. Porter, and J. Morris. 2001. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 18:859-866.
3. Beam, T. R., Jr., D. N. Gilbert, and C. M. Kunin. 1992. General guidelines for the clinical evaluation of anti-infective drug products. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 15(Suppl. 1):S5-S32.
4. Bennett, J. V., J. L. Brodie, E. J. Benner, and W. M. Kirby. 1966. Simplified, accurate method for antibiotic assay of clinical specimens. Appl. Microbiol. 14:170-177.
5. Best, G. K., N. H. Best, and N. N. Durham. 1968. Chromatographic separation of the vancomycin complex. Antimicrob. Agents Chemother. 8:115-119.
6. Christopoulos, A., M. K. Grant, N. Ayoubzadeh, O. N. Kim, P. Sauerberg, L. Jeppesen, and E. E. El-Fakahany. 2001. Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J. Pharmacol. Exp. Ther. 298:1260-1268.
7. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing, approved standard M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Conley, N. S., R. S. Weiner, and J. W. Hiemenz. 1991. Rigors with vancomycin. Ann. Intern. Med. 115:330.
9. Conte, J. E., Jr. 1987. Comparative antibacterial activity of Vancocin and generic vancomycin. Antimicrob. Agents Chemother. 31:333-334.
10. Cook, A., J. P. Acton, and E. Schwartz. 1998. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Congressional Budget Office, Washington, DC. http://www.cbo.gov/ ftpdocs/6xx/doc655/pharm.pdf1-75.
11. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
12. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17:479-501.
13. 7 inocula, abstr. A-986. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
14. Crandon, J. L., M. A. Banevicius, and D. P. Nicolau. 2009. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob. Agents Chemother. 53:1165-1169.
15. Deresinski, S. 2007. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert Rev. Anti Infect. Ther. 5:393-401.
16. Dettelbach, H. R. 1986. A time to speak out on bioequivalence and therapeutic equivalence. J. Clin. Pharmacol. 26:307-308.
17. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat. Rev. Microbiol. 2:289-300.
18. Eagle, H., and A. D. Musselman. 1948. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J. Exp. Med. 88:99-131.
19. Firsov, A. A., S. N. Vostrov, A. A. Shevchenko, and G. Cornaglia. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287.
20. Food and Drug Administration. 2006. New and generic drug approvals. Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
21. Food and Drug Administration. 2001. Guidance for industry: bioanalytical method validation, no. 22. Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services, Rockville, MD.
22. Gardner, C. R., C. T. Walsh, and O. Almarsson. 2004. Drugs as materials: valuing physical form in drug discovery. Nat. Rev. Drug Discov. 3:926-934.
23. Glantz, S. A. 2002. How to test for trends, p. 230-297. In S. A. Glantz (ed.), Primer of biostatistics, 5th ed. McGraw-Hill Companies, Inc., New York, NY.
24. Griffith, R. S. 1981. Introduction to vancomycin. Rev. Infect. Dis. 3(Suppl.): S200-S204.
25. Harris, C. M., H. Kopecka, and T. M. Harris. 1983. Vancomycin: structure and transformation to CDP-I. J. Am. Chem. Soc. 105:6915-6922.
26. Hiramatsu, K. 1998. Vancomycin resistance in staphylococci. Drug Resist. Updat. 1:135-150.
27. Kim, S. J., L. Cegelski, M. Preobrazhenskaya, and J. Schaefer. 2006. Structures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotational-echo double resonance. Biochemistry 45:5235-5250.
28. Lees, P., F. M. Cunningham, and J. Elliott. 2004. Principles of pharmacodynamics and their applications in veterinary pharmacology. J. Vet. Pharmacol. Ther. 27:397-414.
29. Marshall, F. J. 1965. Structure studies on vancomycin. J. Med. Chem. 8:18-22.
30. Moellering, R. C., Jr. 2006. Vancomycin: a 50-year reassessment. Clin. Infect. Dis. 42(Suppl. 1):S3-S4.
31. Nation, R. L., and L. N. Sansom. 1994. Bioequivalence requirements for generic products. Pharmacol. Ther. 62:41-55.
32. Pollack, A. 9 November 2005. Crucial antibiotic rescues biotech maker's finances. N. Y. Times, p. C1-C4.
33. Remenar, J. F., J. M. MacPhee, B. K. Larson, V. A. Tyagi, J. H. Ho, D. A. McIlroy, M. B. Hickey, P. B. Shaw, and O. Almarsson. 2003. Salt selection and simultaneous polymorphism assessment via high-throughput crystallization: the case of sertraline. Org. Process Res. Dev. 7:990-996.
34. Rodriguez, C. A., M. Agudelo, J. C. Cataño, A. F. Zuluaga, and O. Vesga. 2009. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J. Infect. 59:277-280.
35. Senn, S. 1998. In the blood: proposed new requirements for registering generic drugs. Lancet 352:85-86.
36. Somerville, A. L., D. H. Wright, and J. C. Rotschafer. 1999. Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Pharmacotherapy 19:702-707.
37. Taylor, R. B., O. Shakoor, R. H. Behrens, M. Everard, A. S. Low, J. Wangboonskul, R. G. Reid, and J. A. Kolawole. 2001. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 357:1933-1936.
38. Toutain, P. L. 2002. Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. AAPS Pharm. Sci. 4:E38.
39. Vollmerhaus, P. J., E. Breukink, and A. J. Heck. 2003. Getting closer to the real bacterial cell wall target: biomolecular interactions of water-soluble lipid II with glycopeptide antibiotics. Chemistry 9:1556-1565.
40. White, L. O., R. Edwards, H. A. Holt, A. M. Lovering, R. G. Finch, and D. S. Reeves. 1988. The in-vitro degradation at 37 degrees C of vancomycin in serum, CAPD fluid and phosphate-buffered saline. J. Antimicrob. Chemother. 22:739-745.
41. WHO/DMP/RGS. 1998. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for a drug regulatory authority. World Health Organization, Geneva, Switzerland. http://apps.who.int/prequal/info-general/documents/WHO-DMP-RGS-98-5-R.pdf.
42. Zuluaga, A. F., M. Agudelo, C. A. Rodriguez, and O. Vesga. 2009. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clin. Pharmacol. 9:1.
43. Zuluaga, A. F., B. E. Salazar, C. A. Rodriguez, A. X. Zapata, M. Agudelo, and O. Vesga. 2006. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect. Dis. 6:55.